|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
In contrast to JAK2V617F, JAK2ex13InDel does not require an exogenous homodimeric type 1 cytokine receptor to transform Ba/F3 cells, and is capable of activating β common chain family cytokine receptor (IL-3R, IL-5R, granulocyte-macrophage colony stimulating factor receptor) signaling in the absence of ligand, with the maximum effect observed for IL-5R, consistent with the clinical phenotype of eosinophilia.
|
31697804 |
2019 |
|
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The most frequent forms of asthma are identified by sputum/blood eosinophilia and activation of type 2 inflammatory pathways involving interleukins-3, -4, -5, and granulocyte-macrophage colony-stimulating factor.
|
30691714 |
2019 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
This diagnosis should be highly considered in the differential diagnosis of a patient presenting with meningeal symptoms, paraesthesia or hyperaesthesia, and CSF eosinophilia so that treatment can be started early, which is particularly important in children, because of their increased risk of severe disease and mortality.
|
30454904 |
2019 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Granulocyte-macrophage colony-stimulating factor is a potential therapeutic target to reduce esophageal eosinophilia and remodeling.
|
27926989 |
2017 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
In asthma, airway eosinophilia is believed to be mediated by cytokines such as interleukin-5 and granulocyte-macrophage colony stimulating factor (GM-CSF).
|
9525446 |
1998 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study we tested the hypothesis that granulocyte/macrophage-colony stimulating factor (GM-CSF) may contribute to late-responses and tissue eosinophilia and is inhibitable by topical corticosteroid.
|
9876226 |
1998 |
|
Eosinophilic disorder
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We sought to examine the effect of natural seasonal allergen exposure on IL-5 and GM-CSF mRNA expression and nasal eosinophilia and to evaluate the effects of topical corticosteroid therapy on these responses.
|
9802369 |
1998 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, the mechanisms by which GM-CSF contributes to the development of eosinophilia, macrophage granuloma, and fibrosis are discussed in conjunction with the recent findings from us and others.
|
8613693 |
1996 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
These data suggest that increased production of IL-5 and GM-CSF from the abnormal CD(3+)4-(8-) cells might cause eosinophilia.
|
8602991 |
1996 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data support a role for GM-CSF and IL-3 in the eosinophilia characteristic of CHS and show that IL-5 mRNA expression is not a prominent feature of nonallergic inflammation.
|
8335853 |
1993 |
|
Eosinophilic disorder
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The patient's serum did not stimulate eosinophil proliferation or differentiation in comparison with normal serum, however, these data suggest that the abnormal clone with 45,XY,t(12;21)(q23;q22), -17 karyotype may have an increased responsiveness to IL-5 and GM-CSF, resulting in eosinophilia.
|
8353811 |
1993 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
Cytokine messenger RNA expression for IL-3, IL-4, IL-5, and granulocyte/macrophage-colony-stimulating factor in the nasal mucosa after local allergen provocation: relationship to tissue eosinophilia.
|
1560199 |
1992 |
|
Eosinophilic disorder
|
0.100 |
Biomarker
|
group |
BEFREE |
We have used in situ hybridization and an immunoassay to determine whether granulocyte macrophage colony-stimulating factor (GM-CSF) (a cytokine capable of eosinophil activation) is present in the airway of asthmatics (n = 6) who have 37.0 +/- 15.1% airway eosinophilia after endobronchial allergen challenge.
|
1885766 |
1991 |